Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 15 of the 23 sources its claims cite were checked for support.
Abstract
Mitochondrial dysfunction is one of the possible mechanisms by which azole resistance can occur in Candida glabrata. Cells with mitochondrial DNA deficiency (so-called "petite mutants") upregulate ATP binding cassette (ABC) transporter genes and thus display increased resistance to azoles. Isolation of such C. glabrata mutants from patients receiving antifungal therapy or prophylaxis has been rarely reported. In this study, we characterized two sequential and related C. glabrata isolates recovered from the same patient undergoing azole therapy. The first isolate (BPY40) was azole susceptible (fluconazole MIC, 4 μg/ml), and the second (BPY41) was azole resistant (fluconazole MIC, >256 μg/ml). BPY41 exhibited mitochondrial dysfunction and upregulation of the ABC transporter genes C. glabrata CDR1 (CgCDR1), CgCDR2, and CgSNQ2. We next assessed whether mitochondrial dysfunction conferred a selective advantage during host infection by testing the virulence of BPY40 and BPY41 in mice. Surprisingly, even with in vitro growth deficiency compared to BPY40, BPY41 was more virulent (as judged by mortality and fungal tissue burden) than BPY40 in both systemic and vaginal murine infection models. The increased virulence of the petite mutant correlated with a drastic gain of fitness in mice compared to that of its parental isolate. To understand this unexpected feature, genome-wide changes in gene expression driven by the petite mutation were analyzed by use of microarrays during in vitro growth. Enrichment of specific biological processes (oxido-reductive metabolism and the stress response) was observed in BPY41, all of which was consistent with mitochondrial dysfunction. Finally, some genes involved in cell wall remodelling were upregulated in BPY41 compared to BPY40, which may partially explain the enhanced virulence of BPY41. In conclusion, this study shows for the first time that mitochondrial dysfunction selected in vivo under azole therapy, even if strongly affecting in vitro growth characteristics, can confer a selective advantage under host conditions, allowing the C. glabrata mutant to be more virulent than wild-type isolates.
Overview
CoChat Summary
TL;DR
A clinical *Candida glabrata* petite mutant (BPY41) that arose after azole therapy was azole resistant and, despite in vitro growth deficiency, was more virulent and fitter than its azole-susceptible parent (BPY40) in murine systemic and rat vaginal infection models. An in vitro-generated petite mutant (DSY4339) did not show this enhanced virulence, suggesting the origin/selection context of mitochondrial dysfunction matters.
Key findings
- BPY41 was azole resistant (fluconazole MIC >256 μg/ml) versus BPY40 (fluconazole MIC 4 μg/ml), with cross-resistance to itraconazole and voriconazole, and overexpressed *CgCDR1*, *CgCDR2*, *CgSNQ2*, and *CgPDR1* without a detected *CgPDR1* mutation.
- BPY41 showed mitochondrial dysfunction: no growth on glycerol, absent SYTO18 mitochondrial staining, no recoverable mitochondrial DNA, and strongly reduced oxygen consumption.
- BPY41 was more virulent than BPY40 in mice: lower LD50s (BPY41 3.45 × 10^7 CFU immunocompetent and 2.3 × 10^7 CFU immunosuppressed vs. BPY40 7.2 × 10^7 and 6.8 × 10^7 CFU), higher tissue burdens in kidney, spleen, and liver at day 7, and slower vaginal clearance in rats.
- The in vitro-generated petite DSY4339 had higher LD50s (2.81 × 10^8 CFU immunocompetent and 1.65 × 10^8 CFU immunosuppressed) and lowest tissue burdens, with virulence not significantly different from BPY40.
Methods
- Two sequential related clinical *C. glabrata* isolates from the same patient were studied: BPY40 (azole-susceptible parent) and BPY41 (azole-resistant petite mutant); DSY4339 was generated in vitro from BPY40 by ethidium bromide exposure.
- Murine systemic infection models used female BALB/c mice for survival, LD50 determination, and tissue burden (liver, spleen, kidney); a rat vaginal mucosa infection model used oophorectomized female Wistar rats. In vitro and in vivo fitness competitions mixed BPY40 and BPY41 and distinguished them by growth on fluconazole.
- Genome-wide expression was analyzed by custom *C. glabrata* Agilent microarrays with three biological replicates; genes were included if expression changed at least 2-fold between BPY41 and BPY40 in at least two independent experiments with corrected *P* < 0.05. qRT-PCR measured *CgCDR1*, *CgCDR2*, *CgSNQ2*, *CgPDR1*, and *CgYPS*.
Limitations
- The paper states it cannot exclude that the in vitro- or in vivo-generated mitochondrial mutants also contain nuclear mutations that decrease or increase virulence, respectively.
- The paper notes that the exact regulatory mechanisms behind ABC transporter upregulation in petite mutants remain largely unresolved.
- The provided text is truncated in the Results, so later analyses and the full discussion are not available here; the paper’s statement beginning “Our current data cannot confirm…” is cut off.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 5 Not checked · 18 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“upregulation of the ABC transporter genes *C. glabrata CDR1* (*CgCDR1*), *CgCDR2*, and *CgSNQ2*”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Could not verifycites [14] matched to “Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence” (2009) sourceExperimental — accuracy not yet measured
The Results section on ABC-transporter expression reports that CgCDR1, CgCDR2, and CgSNQ2 are not always upregulated together. Searches for BPY41 and for BPY41 with the three gene names found no passage reporting its expression profile; the passage about BPY55 concerns a different strain. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [35] matched to “Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance” (2005) source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“BPY41 exhibited mitochondrial dysfunction”
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
“BPY41 exhibited typical features of a petite phenotype, including the absence of growth in glycerol-containing medium and absence of mitochondrial staining with SYTO18 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Supportedcites [14] matched to “Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence” (2009) source
The Results section, “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates,” identifies BPY41 as having altered mitochondrial respiratory capacity, based on its inability to grow on glycerol as the sole carbon source and defects in mitochondrial DNA. This supports the paraphrase that BPY41 exhibited mitochondrial dysfunction. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, *C. glabrata* can develop azole resistance at a relatively high frequency ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] matched to “Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata” (2001) source
The Results report that azole-susceptible C. glabrata generated fluconazole-resistant cells in vitro at frequencies of 2 × 10−4 to 4 × 10−4. The paper describes this as high-frequency azole resistance, supporting the claim that the yeast can develop azole resistance at a relatively high frequency. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Remarkably, loss of mitochondrial function in *C. glabrata* is associated with acquisition of azole resistance ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] matched to “Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata” (2001) source
The Discussion explicitly links loss of mitochondrial function in C. glabrata to acquisition of azole resistance. The Abstract likewise reports that high-frequency azole resistance acquired in vitro was linked to mitochondrial loss. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > RESULTS > Characteristics of BPY41, a clinical petite mutant isolate.
What the sources say
- Supportedcites [14] matched to “Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence” (2009) source
In Results, under “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates” (page not provided), BPY41 is listed among the azole-resistant isolates that were exceptions to the observed occurrence of CgPDR1 mutations. (LLM, conf=0.93)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
18 more claims · 1 with their cited sources checked
Create a free account to see all 36 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apparently, the inactivation of these metabolic signaling pathways promotes survival during resistance evolution in both species (22).”
From Divergent mitochondrial responses and metabolic signal pathways secure the azole resistance in Crabtree-positive and negative Candida species (2024) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The virulent analyses, based on mortality and fungal tissue burden in both systemic and vaginal murine infection models, suggested higher virulence of BPY41 than BPY40.”
From Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival (2021) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An association of decreased fluconazole susceptibility with mitochondrial dysfunction in C. glabrata has been reported by several laboratories (7–12).”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction in pathogenic fungi or model yeast causes altered susceptibilities to antifungal drugs.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Ferrari et al. (9) demonstrated that a mitochondrial deficiency in C. glabrata strain BPY41 caused resistance to azoles associated with the upregulation of ABC transporter genes CgCDR1, CgCDR2, and CgSNQ2.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Dujon, B., Sherman, D., Fischer, G., Durrens, P., Casaregola, S., Lafontaine, I., de Montigny, J., Marck, C., Neuvéglise, C., Talla, E., et al. (2004) · Nature · doi:10.1038/nature02579 · Cited by 1,623 · cited 1×
“species, to which Saccharomyces cerevisiae also belongs (13).”
BackgroundChanging epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524 · cited 1×
“glabrata has increased in the last decade, and this species now ranks as the second or third most frequently isolated Candida species among all reported cases of candidiasis (30).”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 3×
“The major mechanism involved in azole resistance is based on the overexpression of ATP binding cassette (ABC) transporters (34).”
BackgroundSelf-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Self-citationFerrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 10×
“CgCDR1, CgCDR2, CgSNQ2, and CgPDR1 are overexpressed in BPY41, which is consistent with the azole resistance phenotype (14, 35).”
BackgroundMethodInfluentialSelf-citationKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284 · cited 15×
“The rat was considered colonized when at least 1 CFU was present in the vaginal lavage fluid.”
BackgroundMethodInfluentialRSAT: regulatory sequence analysis tools
Thomas-Chollier, M., Sand, O., Turatsinze, J.-V., Janky, R., Defrance, M., Vervisch, E., Brohee, S., & van Helden, J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn304 · Cited by 278
Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants
DeRisi, J., van den Hazel, B., Marc, P., Balzi, E., Brown, P., Jacq, C., & Goffeau, A. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01294-1 · Cited by 276
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Self-citation
Cited by
Items 101–145 of 145
Investigating Candida glabrata Urinary Tract Infections (UTIs) in Mice Using Bioluminescence Imaging
Schrevens, S., & Sanglard, D. (2021) · Journal of Fungi · doi:10.3390/jof7100844 · Cited by 9
Self-citationKumari, S., Kumar, M., Esquivel, B. D., Wasi, M., Pandey, A. K., Khandelwal, N., Mondal, A. K., White, T. C., Prasad, R., & Gaur, N. A. (2022) · mBio · doi:10.1128/mbio.03545-21 · Cited by 9
“report also suggested the upregulation of CgYCF1, CgYBT1, and CgYOR1 in azole-resistant petite isolates (21).”
BackgroundyEvo: A modular eukaryotic genetics and evolution research experience for high school students
Taylor, M. B., Warwick, A. R., Skophammer, R. G., Boyer, J. M., Geck, R. C., Gunkelman, K., Walson, M., Rowley, P. A., & Dunham, M. J. (2024) · Ecology and Evolution · doi:10.1002/ece3.10811 · Cited by 5
Nickels, T. J., & Cunningham, K. W. (2025) · mSphere · doi:10.1128/msphere.00270-25 · Cited by 8
“Mitochondrial deficiencies potently activate the Pdr1 transcription factor and induce the expression of several target genes such as CDR1 (39–41).”
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Zhu, H., Zhu, N., Peng, L., Zhang, B., Yu, Q., & Li, M. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa050 · Cited by 8
Mechanisms of Antifungal Drug Resistance
Francesconi, F., Jálkh, A. P., Lupi, O., & Khalfe, Y. (2021) · Updates in clinical dermatology · doi:10.1007/978-3-030-68321-4_8 · Cited by 8
Uncovering the role of mitochondrial genome in pathogenicity and drug resistance in pathogenic fungi
Ni, Y., & Gao, X. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1576485 · Cited by 11
“For pathogenic fungi, such as C. glabrata , the loss of the mitochondrial genome can result in increased drug resistance (Sanglard et al., 2001; Batova et al., 2008; Ferrari et al., 2011).”
Tian, Y., Gao, N., Ni, Q., Mao, Y., Dong, D., Huang, X., Jiang, C., Li, Z., Zhang, L., Wang, X., et al. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy038 · Cited by 6
Beyer, R., Zangl, I., Seidl, B., Pap, I.-J., Lackner, M., Strauss, J., Willinger, B., & Schüller, C. (2025) · mSystems · doi:10.1128/msystems.00786-25 · Cited by 9
Geck, R. C., Moresi, N. G., Anderson, L., Students, Y., Addepalli, I., Aggarwal, D., Agnihotri, P., Ali, A. A., Amorosi, C. J., Anand, A., et al. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae148 · Cited by 9
“…frequently selected for in both caffeine and clo-trimazole, confirming previous reports that mtDNA loss increases growth in the presence of azoles and caffeine, at least partly by increased Pdr3 activity (Bard et al. 1980; Hallstrom and Moye-Rowley 2000; Ferrari et al. 2011; Taylor et al. 2022).”
BackgroundHwang, I. J., Kwon, Y. J., Lim, H. J., Hong, K. H., Lee, H., Yong, D., Won, E. J., Byun, S. A., Lee, G. Y., Kim, S. H., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00883-24 · Cited by 6
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., Cabrera, N., İlkit, M., Desai, J. V., Gabaldón, T., Shor, E., & Perlin, D. S. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae035 · Cited by 7
“Overall, these observations suggest that the intracellular growth defect of FLZR isolates carrying GOF mutations in PDR1 , but not mitochondrial dysfunction (petite), can be rescued by fks mutations conferring ECR, reinforcing our previous observations that isogenic and clinical MDR strains have…”
Awadi, A. (2017) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-017-0070-2 · Cited by 6
“Among others, the fact that mitochondrial function is necessary for virulence was suggested by a recent report of more virulent mitochondrial mutants of Candida glabrata [33].”
BackgroundHatami, F., Manifar, S., Asghari-Paskiabi, F., Amiri, F. B., Nojoumi, S. A., & Jahanshiri, Z. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105757 · Cited by 7
Resistance of Candida glabrata to drugs and the host immune system
Musa, K. B., Ahmed, M. A., Shahpudin, S. N. M., Kamal, L. Z. M., Sandai, R., Tabana, Y., & Sandai, D. A. (2018) · Clinical Microbiology and Infectious Diseases · doi:10.15761/cmid.1000145 · Cited by 4
Microarray Technologies in Fungal Diagnostics
Rupp, S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_22 · Cited by 7
Bednarek, A., Kabut, A., Rąpała‐Kozik, M., & Satała, D. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0995 · Cited by 4
“Furthermore, Ferrari et al. [39] highlighted the signi fi cance of Yps in virulence, indicating that strains of N. glabratus that are resistant to azoles and exhibit mitochondrial dysfunction (BPY41) overexpress genes encoding these proteases.”
Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant Candida Species
Beyda, N. D., Regen, S., Lewis, R. E., & Garey, K. W. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0132-3 · Cited by 3
“glabrata, these adaptations have been associated with virulence of experimental isolates in animal infection models [20, 21].”
BackgroundThe cell wall protein Rhd3/Pga29 is over-expressed inCandida albicansupon micafungin treatment
Vavala, E., Mignogna, G., Spano, F., Stringaro, A., Colone, M., Sanguinetti, M., Maras, B., & Angiolella, L. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000091 · Cited by 5
Self-citationHost-Fungal Interactions: Pathogenicity versus Immunity
Tavanti, A., Naglik, J. R., & Osherov, N. (2012) · International Journal of Microbiology · doi:10.1155/2012/562480 · Cited by 5
Doxorubicin selects for fluconazole-resistant petite mutants in Candida glabrata isolates
Schulz, B., Knobloch, M., Weber, K., & Ruhnke, M. (2012) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2012.04.002 · Cited by 5
Taylor, M. B., Skophammer, R. G., Warwick, A. R., Boyer, J. M., Students, Y., Walson, M., Large, C. R. L., Hickey, A. S.-M., Rowley, P. A., & Dunham, M. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.02.442375 · Cited by 3
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.15.545195 · Cited by 3
Human Fungal Pathogens and Drug Resistance Against Azole Drugs
Bhetariya, P. J., Sharma, N., Singh, P., Tripathi, P., Upadhyay, S. K., & Gautam, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_18 · Cited by 4
A novel Candida glabrata doxycycline-inducible system for in vitro/in vivo use
Schrevens, S., & Sanglard, D. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac046 · Cited by 3
“This is due to the limited existing in vivo studies on this organism (Ferrari et al. 2011a,b, Nakayama et al. 2011, Schrevens et al. 2022).”
BackgroundSelf-citationMechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Using Bioluminescence to Image Candida glabrata Urinary Tract Infections in Mice
Schrevens, S., Torelli, R., Sanguinetti, M., & Sanglard, D. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3155-3_17 · Cited by 1
Self-citationIn the Crossroad Between Drug Resistance and Virulence in Fungal Pathogens
Cavalheiro, M., & Teixeira, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-030-00683-9_7 · Cited by 1
Membrane et paroi fongiques : des rôles clés dans la résistance aux antifongiques
Garnaud, C., & Cornet, M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30062-9 · Cited by 6
Dhar, R., Missarova, A. M., Lehner, B., & Carey, L. B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/346361 · Cited by 1
“9 resistance to some antifungal drugs [54-56] and respiration deficient strains are often isolated 222 from drug-treated patients [57-59].”
BackgroundArastehfar, A. A., Daneshnia, F., Hovhannisyan, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.03.547612 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Shingú-Vázquez, M., & Traven, A. (2011)
Sun, N. (2013) · DigitalGeorgetown (Georgetown University Library)
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
Role of Mitochondria in Fungal Drug Resistance
Pasrija, R., & Kundu, D. (2019) · Springer eBooks · doi:10.1007/978-981-32-9449-3_8
Yoo, K., Oliveira, N. K., Bhattacharya, S., & Fries, B. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.26.586817
Johnson, Z., Nadim, F., & Zubko, M. K. (2025) · Microorganisms · doi:10.3390/microorganisms13010099
Klimova, N. G., Patel, H., Devaux, F., & Turcotte, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.25.645289
Geng, Y., Wang, X., Zhang, S., Liu, X., Liu, H., Guo, X., Lu, Y., Gong, J., & Qin, Z. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1693528
Malta-Luís, C., Romeo, G., Francescato, G., Mariano, C. V., Mil‐Homens, D., Petronilho, A., & Pimentel, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709283
Transcriptional networks of the stress responses in the human pathogen Candida glabrata
Thiébaut, A. (2018) · theses.fr (ABES) · doi:10.70675/323c74a8z1ae4z4123za081zd0af3ecf65ae
Gador‐Whyte, A., Seemann, T., Judd, L. M., Horan, K., Lacey, J. A., Traven, A., Daniel, D., Guérillot, R., Giulieri, S. G., Vogrin, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733717
Malta-Luís, C., Romeo, G., Francescato, G., Mariano, C. V., Mil‐Homens, D., Petronilho, A., & Pimentel, C. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00759-26
“Although fluconazole did not induce petite mutants under our treatment conditions, it is well known to promote this phenotype in vitro , and petite clinical strains have been isolated from fluconazoletreated patients (34, 58, 59).”
Metadata
- Authors
- Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- Department of Infectious, Parasitic, and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-05
- Volume
- 55
- Issue
- 5
- Pages
- 1852-1860
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3088236
- OpenAlex
- W2098964280
- Semantic Scholar
- 8b330e8c08f4c329027f81adbc47ae8af0f15169
- Cited by
- 144
- References
- 44
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 12 · 2023: 10 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 12 · 2012: 12
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida glabrata, azole resistance, mitochondrial dysfunction, petite mutants, ABC transporters, CDR1, CDR2, fluconazole, fungal virulence, antifungal therapy, cell wall remodeling, oxidative stress response, gene expression profiling, fitness cost
- MeSH terms
- Animals, Azoles, Female, Mice, Inbred BALB C, Microbial Sensitivity Tests, Molecular Sequence Data, Virulence, Gene Expression Regulation, Fungal, Computational Biology, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Microarray Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.